Login
Cell Therapies, Cancer & Rare Diseases
- Pininvest Analysis
Cell therapies have opened new treatment fields by cell inhibitors, gene modification, or even gene replacement
By gene modification after extraction of white blood cells from a leukemia-fighting patient, the cells are bolstered for more vigorous attack of cancer cells and reinjected in the patient; the Novartis treatment researched by University of Pennsylvania has been approved by the FDA in August ’17 and more than 76 applications have been accepted for testing in this promising field, possibly extending the procedure to some forms of brain and lung cancer patients - Check our note "Immunotherapy by adaptive cell transfer (ACT)' for more information
Gene replacement aims disease caused by a single faulty gene and the first treatment, targeting vision loss due to genetic mutation, introduced by Spark Therapeutics, is the first of its kind to be approved by FDA (December ’17)
Cell Therapies, Cancer & Rare Diseases • Updated:
| Name | Ticker | Exchange | Sector | Industry | Currency | Cur.Price | Mkt.Cap | Perf. | Vol. | Vol. Contrib. | MDD |
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | ADAP | NASDAQ | Health Care | Biopharmaceuticals | USD | 4.94 | 518 M | -42.7% | 76% | 2% | -73% |
|
|
| Amgen Inc. | AMGN | NASDAQ | Health Care | Biopharmaceuticals | USD | 188.34 | 117 B | 4.1% | 23% | 1% | -15% |
|
|
| Bellicum Pharmaceuticals | BLCM | NASDAQ | Health Care | Biopharmaceuticals | USD | 3.17 | 137 M | -52.0% | 67% | 2% | -71% |
|
|
| bluebird bio, Inc. | BLUE | NASDAQ | Health Care | Biopharmaceuticals | USD | 137.03 | 7.5 B | -35.8% | 52% | 2% | -61% |
|
|
| Celgene | CELG | NASDAQ | Health Care | Drug Manufacturers -Specialty Pharma | USD | 90.69 | 63 B | -4.8% | 35% | 2% | -39% |
|
|
| Cellectis SA | CLLS | NASDAQ | Health Care | Biopharmaceuticals | USD | 17.45 | 627 M | -46.6% | 49% | 1% | -60% |
|
|
| Celyad (ADR) | CYAD | NASDAQ | Health Care | Biopharmaceuticals | USD | 20.38 | 201 M | -51.2% | 66% | 1% | -63% |
|
|
| Clovis Oncology, Inc. | CLVS | NASDAQ | Health Care | Biopharmaceuticals | USD | 25.49 | 1.3 B | -52.9% | 77% | 2% | -81% |
|
|
| Corvus Pharmaceuticals | CRVS | NASDAQ | Health Care | Biopharmaceuticals | USD | 4.13 | 121 M | -49.1% | 65% | 2% | -76% |
|
|
| CRISPR Therapeutics | CRSP | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 31.52 | 1.6 B | -21.2% | 73% | 4% | -69% |
|
|
| Editas Medicine | EDIT | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 20.08 | 960 M | -40.6% | 66% | 3% | -59% |
|
|
| Gilead Sciences Inc. | GILD | NASDAQ | Health Care | Biopharmaceuticals | USD | 67.59 | 87 B | -14.1% | 26% | 1% | -26% |
|
|
| Immunogen | IMGN | NASDAQ | Health Care | Biopharmaceuticals | USD | 5.65 | 842 M | -49.9% | 67% | 2% | -70% |
|
|
| Intellia Therapeutics | NTLA | NASDAQ | Health Care | Biopharmaceuticals | USD | 13.99 | 607 M | -44.1% | 72% | 3% | -67% |
|
|
| Intercept Pharmaceuticals | ICPT | NASDAQ | Health Care | Drug Manufacturers -Specialty Pharma | USD | 110.82 | 3.3 B | 81.2% | 55% | 7% | -33% |
|
|
| Invitae Corporation | NVTA | NYSE | Health Care | Medical Laboratories & Research | USD | 16.06 | 1.2 B | 147.8% | 71% | 13% | -49% |
|
|
| MacroGenics | MGNX | NASDAQ | Health Care | Biopharmaceuticals | USD | 21.84 | 923 M | -6.3% | 102% | 4% | -66% |
|
|
| NantKwest, Inc. | NK | NASDAQ | Health Care | Biopharmaceuticals | USD | 1.13 | 90 M | -74.6% | 88% | 1% | -80% |
|
|
| Neos Therapeutics | NEOS | NASDAQ | Health Care | Drug Manufacturers -Specialty Pharma | USD | 2.40 | 71 M | -74.1% | 60% | 1% | -83% |
|
|
| Novartis | NVS | NYSE | Health Care | Drug Manufacturers - Diversified | USD | 89.88 | 208 B | 6.8% | 17% | 1% | -17% |
|
|
| Regeneron Pharmaceuticals Inc. | REGN | NASDAQ | Health Care | Biopharmaceuticals | USD | 423.97 | 46 B | 27.6% | 31% | 3% | -18% |
|
|
| REGENXBIO | RGNX | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 48.13 | 1.7 B | 79.3% | 71% | 10% | -52% |
|
|
| Sangamo Therapeutics | SGMO | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 8.79 | 897 M | -62.3% | 86% | 2% | -71% |
|
|
| Spark Therapeutics | ONCE | NASDAQ | Health Care | Biopharmaceuticals | USD | 52.77 | 2.0 B | -3.2% | 64% | 4% | -62% |
|
|
| uniQure | QURE | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 37.46 | 1.4 B | 52.2% | 69% | 7% | -47% |
|
|
| Vericel | VCEL | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 19.49 | 845 M | 168.8% | 83% | 15% | -38% |
|
|
| ZIOPHARM Oncology | ZIOP | NASDAQ | Health Care | Biopharmaceuticals | USD | 2.59 | 369 M | -32.4% | 79% | 3% | -67% |
|